Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Regains Nasdaq Compliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics has regained compliance with a Nasdaq rule that its stock meet a minimum $1 share price and will remain listed on the exchange, it announced after the close of the market on Thursday.

The company said that it has received notice from Nasdaq that it will continue being listed on the Nasdaq Capital Market under ticker symbol "ROSGD" through Aug. 3, then revert back to ticker symbol "ROSG" on Aug. 4.

Nasdaq rules stipulate that in order to be traded on its Capital Market, a company's stock must have a closing bid price of at least $1 for 10 consecutive trading days. Rosetta Genomics had been given until Aug. 8 to satisfy the condition.

Earlier this month, the Israeli microRNA-based molecular diagnostics company underwent a one-for-four reverse stock split to satisfy the requirement.

At the close of the market on Thursday, shares of Rosetta Genomics were down 6 percent at $1.50.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.